QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH™ Platform Expands Portfolio
Food bioscience company Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) strategic focus for 2018 is on out-licensing its proprietary technology, DehydraTECH™. The company intends to out-license to third-party partners using a high margin royalty model. An article discussing the company’s drug delivery platform reads: “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a research-driven company that has developed and out-licenses a patented drug delivery platform called DehydraTECH™ that changes the way active pharmaceutical ingredients (“APIs”) enter the body orally. According to a new report by Million Insights (http://ibn.fm/iaAZ9), the global API market is anticipated to reach $239.8 billion by 2025, with…